2-[(2-氯-1,1,2-三氟乙基)硫烷基]苯胺 | 81029-02-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 2-[(2-氯-1,1,2-三氟乙基)硫烷基]苯胺
• 中文别名: 2-[(2-氯-1,1,2-三氟乙基)硫代]苯胺；2-(2-氯-1,1,2-三氟乙硫基)苯胺
• 英文名称: 2-[(2-Chloro-1,1,2-trifluoroethyl)thio]aniline
• 英文别名: 2-(2-chloro-1,1,2-trifluoroethyl)sulfanylaniline
• CAS: 81029-02-9
• 化学式: C₈H₇ClF₃NS
• 分子量: 241.66
• InChiKey: FCZIJASKFXRHTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2930909090

文献信息

• Inhibitors of C-FMS kinase
  申请人：Player R. Mark

  公开号：US20050113566A1

  公开（公告）日：2005-05-26

  The invention relates to compounds of Formula I: wherein A is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of -C 1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF 3 , alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF 3 , —OCO-alkyl, —CORA, —CN, —C(NH)NH 2 , —COOR a , —CONR a R b , —N(R a )COR b , —NO 2 , —SO 2 R a , —SO 3 R a or —SO 2 NR a R b ; or a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with one or more of -C 1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF 3 , alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF 3 , —OCO-alkyl, —COR a , —CN, —C(NH)NH 2 , —COOR a , —CONR a R b , —N(R a )COR b , —NO 2 , —SO 2 R a , —SO 3 R a or —SO 2 NR a R b ; R 1 is —H, aryl, —COR a , —COR a , —COOR a , —CONR a R b , —SO 2 R a or —SO 2 NR a R b ; X is —CO—, —C(═NH)—, —CS—, —CON(R a )—, —CS(NR a )—, —SO 2 — or —CR a R b —; Y is —S—, —SO—, —SO 2 —, —O— or direct link; R 2 is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which may be optionally substituted with one or more halogens; and W is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C 1-4 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, halogen, hydroxy, —CF 3 , alkoxy, aryloxy, arylalkoxy, —OCF 3 , —COR a , —CN, —C(NH)NH 2 , —COOR a , —CONR a R b , —NHCOR a R b , —NHSO 2 R a , —NO 2 , —SOR a , —SO 3 R a or —SO 2 NR a R b ; or a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heterocyclic or heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with -C 1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, —CF 3 , alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF 3 , —OCO-alkyl, —OCO-alkylamino, —OCO-alkylamido, COR a , —CN, —C(NH)NH 2 , —COOR a , —CONR a R b , —N(R a )COR b , —NO 2 , —SO 2 R a , —SO 3 R a or —SO 2 NR a R b ; as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

  该发明涉及Formula I的化合物： 其中A为苯基、萘基或联苯基，每种基团可以选择性地取代一个或多个以下基团之一：-C1-6烷基、氨基、氨基烷基、羟基烷基、烷氧基烷基、磺胺基烷基、胍基烷基、杂环芳基、卤素、羟基、—CF3、烷氧基、芳基、芳基烷基、杂环芳基、芳基氧基、芳基烷氧基、—OCF3、—OCO-烷基、—CORA、—CN、—C(NH)NH2、—COORa、—CONRaRb、—N(Ra)CORb、—NO2、—SO2Ra、—SO3Ra或—SO2NRaRb；或者为含有1至4个异原子（N、O或S）的5至7成员的单环或8至10成员的双环杂芳环，可以选择性地取代一个或多个以下基团之一：-C1-6烷基、氨基、氨基烷基、羟基烷基、烷氧基烷基、磺胺基烷基、胍基烷基、杂环芳基、卤素、羟基、—CF3、烷氧基、芳基、芳基烷基、杂环芳基、芳基氧基、芳基烷氧基、—OCF3、—OCO-烷基、—CORA、—CN、—C(NH)NH2、—COORa、—CONRaRb、—N(Ra)CORb、—NO2、—SO2Ra、—SO3Ra或—SO2NRaRb；R1为—H、芳基、—CORa、—CORa、—COORa、—CONRaRb、—SO2Ra或—SO2NRaRb；X为—CO—、—C(═NH)—、—CS—、—CON(Ra)—、—CS(NRa)—、—SO2—或—CRaRb—；Y为—S—、—SO—、—SO2—、—O—或直链；R2为烷基、环烷基、杂环烷基、芳基或杂芳基，每种基团可以选择性地取代一个或多个卤素；W为苯基、萘基或联苯基，每种基团可以选择性地取代一个或多个以下基团之一：C1-4烷基、氨基、氨基烷基、羟基烷基、烷氧基烷基、卤素、羟基、—CF3、烷氧基、芳基氧基、芳基烷氧基、—OCF3、—CORa、—CN、—C(NH)NH2、—COORa、—CONRaRb、—NHCORaRb、—NHSO2Ra、—NO2、—SORa、—SO3Ra或—SO2NRaRb；或者为含有1至4个异原子（N、O或S）的5至6成员的单环或8至10成员的双环杂环或杂芳环，可以选择性地取代一个或多个以下基团之一：-C1-6烷基、氨基、氨基烷基、羟基烷基、烷氧基烷基、杂环芳基、卤素、羟基、—CF3、烷氧基、芳基、芳基烷基、杂环芳基、芳基氧基、芳基烷氧基、—OCF3、—OCO-烷基、—OCO-烷基氨基、—OCO-烷基酰胺基、CORa、—CN、—C(NH)NH2、—COORa、—CONRaRb、—N(Ra)CORb、—NO2、—SO2Ra、—SO3Ra或—SO2NRaRb；以及这些化合物的溶剂化合物、水合物、互变异构体或药学上可接受的盐，能抑制蛋白酪氨酸激酶，尤其是c-fms激酶。
• C-fms kinase inhibitors
  申请人：Player R. Mark

  公开号：US20050004112A1

  公开（公告）日：2005-01-06

  The invention is directed to compounds of Formulae I, II and III: wherein A, R 1 , R 2 , R 3 , R 4 , X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

  本发明涉及式I、II和III的化合物：其中A、R1、R2、R3、R4、X、Y和W在说明书中列出，以及其溶剂化物、水合物、互变异构体或药学上可接受的盐，其抑制蛋白酪氨酸激酶，特别是c-fms激酶。
• c-fms kinase inhibitors
  申请人：Player R. Mark

  公开号：US20060258666A1

  公开（公告）日：2006-11-16

  The invention is directed to compounds of Formula II: wherein A, R 1 , R 2 , R 3 , R 4 , X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

  本发明涉及公式II的化合物： 其中A、R1、R2、R3、R4、X、Y和W在说明书中有所阐述，以及其溶剂化物、水合物、互变异构体或药学上可接受的盐，其可抑制蛋白酪氨酸激酶，特别是c-fms激酶。
• C-FMS KINASE INHIBITORS
  申请人：3-DIMENSIONAL PHARMACEUTICALS, INC.

  公开号：EP1631560A2

  公开（公告）日：2006-03-08
• Negative curable dye-containing composition, color filter, and method of manufacturing the same
  申请人：Takakuwa Hideki

  公开号：US20070072096A1

  公开（公告）日：2007-03-29

  The invention provides a negative curable dye-containing composition including at least one compound selected from amine and pyridine compounds, a phthalocyanine dye soluble in an organic solvent, a photopolymerization initiator, and a radical polymerizable monomer, a color filter formed by using the same, and a manufacturing method of the color filter.

表征谱图